Evidence map›Paper›PMID 39078248›Full record

ArticleAndrology2025

Testicular ultrasonographic features predict future risk for bilateral testicular germ cell tumour: A long-term single centre follow-up study.

Marta Tenuta, Paola Mazzotta, Franz Sesti, Francesco Angelini, Alain J Gelibter, Iolanda Speranza, Donatella Paoli, Francesco Lombardo, Antonella Anzuini, Fabio Massimo Magliocca and 7 more

Abstract read
In one paragraph

Article in Andrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marta TenutaDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-7476-0737
Paola MazzottaDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.
Franz SestiDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0003-3850-627X
Francesco AngeliniDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.
Alain J GelibterDivision of Oncology B, Department of Radiological, Oncological and Anatomopathological Sciences, Sapienza University, Rome, Italy.
Iolanda SperanzaDivision of Oncology A, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy.
Donatella PaoliDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-9699-8703
Francesco LombardoDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-6943-2966
Antonella AnzuiniDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.
Fabio Massimo MaglioccaDepartment of Radiological, Oncological and Pathological Sciences, Sapienza University, Rome, Italy.
Giorgio FrancoDepartment of Maternal and Child Health and Urological Sciences, Sapienza University, Rome, Italy.
Enrico CortesiDivision of Oncology B, Department of Radiological, Oncological and Anatomopathological Sciences, Sapienza University, Rome, Italy.
Daniele SantiniDivision of Oncology A, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy.
Andrea LenziDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.
Daniele GianfrilliDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-2682-8266
Andrea M IsidoriDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-9037-5417
Carlotta PozzaDivision of Endocrinology and Andrology, Department of Experimental Medicine, Sapienza University, Rome, Italy.ORCID 0000-0002-1147-6114

Funding

European Union Next Generation EU through the Italian Ministry of University and Research: PNRR M4C2-I1.3 Project PE_00000019 "HEALITALIA" CUPB53C22004000006Italian Ministry of Health: PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin (PROMETEO) project NET-2018-12365454
6 · The paper itself

Abstract

backgroundBilateral testicular germ cell tumours (B-GCT) are rare, with an incidence of 2-5%, and can be classified as synchronous (sB-GCT) or metachronous (mB-GCT). Our study aimed to identify clinical, biochemical, and radiological risk factors for mB-GCT in a cohort of patients with GCT at a single tertiary referral centre.

methodsThis retrospective case-control study included patients with GCT referred to Policlinico Umberto I-Sapienza University of Rome, from 2005 to 2023. We evaluated clinical history, testicular ultrasound features, hormone levels, semen analysis, histological characteristics, staging, and treatments. mB-GCTs were compared with unilateral GCT patients with a follow-up longer than the median time-to-onset of the second tumour.

resultsOf 319 patients, 52 experienced B-GCT, with a median time-to-onset of the second tumour of 62 months (range: 8-229). The mB-GCT group showed higher gonadotropin levels (FSH 13.6mUI/mL vs. 7.4mUI/mL, p < 0.001; LH 6.6mUI/mL vs. 3.9mUI/mL, p = 0.004), lower sperm concentration (27 × 10

conclusionsHistological features of the first tumour or its treatment do not influence the onset of a second tumour. However, low residual testis volume, inhomogeneous echotexture, and microlithiasis significantly increase this risk. A comprehensive evaluation of the residual testis at baseline is essential for developing a personalised surveillance programme in GCT survivors, with regular ultrasound follow-up recommended beyond the conventional 5-year limit.

Indexed as

Neoplasms, Germ Cell and EmbryonalNeoplasms, Second PrimaryTesticular NeoplasmsTestisAdultCase-Control StudiesFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesRisk FactorsUltrasonographyYoung Adultbilateral testicular tumoursmicrolithiasismixed germ cell tumoursseminomatesticular ultrasound

Identifiers

PMID39078248
PMCPMC11867925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.